Introduction & Agenda
- Letter to Participants from Drs. Mikhail Kosiborod and Larry Sperling
- Managing CV Disease Risk in Diabetes Roundtable Agenda
- Interactive Table Discussion Questions
Cardiovascular Outcomes Trials in T2DM
- Novel Diabetes Drugs and the Cardiovascular Specialist (JACC – Sattar et al. 2017)
- Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes (AJM – Paneni et al. 2017)
- Shifting Paradigms in the Medical Management of Type 2 Diabetes: Reflections on Recent Cardiovascular Outcome Trials (JGIM– Ismail-Belgi et al. 2017)
- Cardiovascular safety outcomes of new antidiabetic therapies (AJHP– LeBras et al 2017)
Clinical Guidance
- ADA Standards of Medical Care in Diabetes: Chapter 8. Pharmacologic Approaches to Glycemic Treatment (Diabetes Care 2017)
- ADA Standards of Medical Care in Diabetes: Chapter 9. Cardiovascular Disease and Risk Management (Diabetes Care 2017)
- Clinical Update: Cardiovascular Disease in Diabetes Mellitus Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus – Mechanisms, Management, and Clinical Considerations (Circulation – Low Wang et al. 2016)
- Why Don't Diabetes Patients Achieve Recommended Risk Factor Targets? Poor Adherence versus Lack of Treatment Intensification (JGIM – Schmittdiel et al. 2008)
- Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2017 Executive Summary (Endocrine Practice – Garber et al. 2017)
Care Coordination
- 2015 ACC Health Policy Statement on Cardiovascular Team-Based Care and the Role of the Advanced Practice Provider (JACC – Brush, et al. 2015)
- The CardioMetabolic Health Alliance: Working Toward a New Care Model for the Metabolic Syndrome (JACC – Sperling et al. 2015)
- A National Effort to Prevent Type 2 Diabetes: Participant-Level Evaluation of CDC's National Diabetes Prevention Program (Diabetes Care – Ely et al. 2017)
Diabetes Collaborative Registry
- Diabetes Collaborative Registry Data Collection Form
- Quality of care of the initial patient cohort of the Diabetes Collaborative Registry presented (ADA.16 – Arnold et al. 2016)
- Defining the potential impact of the EMPA-REG OUTCOMES® trial on improving cardiovascular outcomes of patients in the Diabetes Collaborative Registry (EASD.16 – Arnold et al. 2016)
- Using The Diabetes Collaborative Registry (DCR) To Estimate the Potential Real-world Impact of The LEADER Trial On Improving Cardiovascular Outcomes in Patients with Diabetes at High Cardiovascular Risk (ACC.17 – Arnold et al. 2017)
- Assessing the Personalization of Glycemic Management in Clinical Practice: an Analysis of the Diabetes Collaborative Registry (AHA.16 – Arnold et al. 2016)
- Using The Diabetes Collaborative Registry (DCR) To Estimate the Potential Real-world Impact of The IRIS Trial On Improving Outcomes in Patients with Cerebrovascular Disease (AHA.16 – Arnold et al. 2016)
- Diabetes Collaborative Registry Methods Manuscript: Improving the Quality of Cardiometabolic Care for Patients with Type 2 Diabetes in the United States (Diabetes Care – Arnold et al. 2017)
Supplemental Reading Not Included in Book
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes (EMPA-REG OUTCOME) (NEJM – 2016)
- Insulin Resistance Intervention after Stroke (IRIS) (NEJM – 2016)
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER) (NEJM – 2016)
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) (NEJM – 2016)
- A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease (BARI 2D) (NEJM – 2009)
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes (CANVAS) (NEJM – 2017)
- Provider Interactions and Cost Affect Type 2 Diabetes Mellitus Patients’ Perceptions of Care Quality and Adherence (ADA.17 – Simacek et al. 2017)
Presentations
- Session 1. Presentation 1. Paradigm Shift in CRM management. Kosiborod 06 19 17.v1
- Session 1. Presentation 2. The Evolution of CV Outcomes Trials in T2DM Over the Years_McGuire
- Session 1. Presentation 3. Recent Breakthroughs in CVOTs in T2DM_Scirica
- Session 2. Presentation 1. Wong ND ACC June 2017 Managing DM Risks and Role of CV clinicians 061817
- Session 2. Presentation 2. Utilizing Antidiabetic Agents to Reduce CV Disease Risk in Patients with T2DM_LaSalle
- Session 2. Presentation 3. Barriers to implementation T2DM_Birtcher
- Session 3. Presentation 1. Adapting the Heart Team Approach for the Care of High Patients with T2DM_Eckel.Sperling
- Session 3. Presentation 2. Leveraging Registry Data to Improve How We Manage CV Disease Risk in Patients with T2DM_Arnold
- Session 3. Presentation 3. Redefining Quality of Care in T2DM Patients with CV Disease_Magwire